In patients with B‐ALL treated with anti‐CD19 CAR‐T cells, miR‐148a‐3p and miR‐375 could be potential ncRNA biomarkers for the response to CAR‐T cells. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.